Bone Turnover Markers: Use in Fracture Prediction

J Clin Densitom. 2017 Jul-Sep;20(3):346-352. doi: 10.1016/j.jocd.2017.06.020. Epub 2017 Jul 14.

Abstract

Bone turnover markers (BTMs) provide us with a noninvasive approach to studying bone turnover and they can be measured easily and with good precision, especially using automated analyzers. BTMs increase at menopause, and these higher levels are associated with more rapid bone loss. In some but not all studies, they are also associated with greater risk of fracture. However, the evidence base for use as predictors of fracture is not robust, and so BTMs have not been included in fracture prediction models. Further research is needed, and this might include (1) use of reference analytes such as C-telopeptide of type I collagen and procollagen I N-propeptide, measured using automated analyzers in subjects in the fasting state on more than 1 occasion; (2) careful collection of vertebral fractures, which would be the primary endpoint; and (3) common approach to statistical analyses with results expressed as hazard ratio per standard deviation of increase in BTM. We believe that by improving our approach to studying the relationship between BTMs and fracture risk, any association will become clearer and that in the future we might then be able to include BTMs in our fracture prediction models.

Keywords: Bone resorption; bone turnover markers; fracture; osteocalcin; osteoporosis.

Publication types

  • Review

MeSH terms

  • Biomarkers / blood
  • Bone Remodeling*
  • Collagen Type I / blood*
  • Humans
  • Osteoporosis, Postmenopausal / blood*
  • Osteoporosis, Postmenopausal / complications
  • Osteoporotic Fractures / blood
  • Osteoporotic Fractures / etiology*
  • Peptide Fragments / blood*
  • Peptides / blood*
  • Predictive Value of Tests
  • Procollagen / blood*
  • Risk Assessment / methods

Substances

  • Biomarkers
  • Collagen Type I
  • Peptide Fragments
  • Peptides
  • Procollagen
  • collagen type I trimeric cross-linked peptide
  • procollagen Type I N-terminal peptide